Holen Sie sich die Stockscreener-App
0.5434
2.58%
-0.0144
Ensysce Biosciences Inc Aktie (ENSC) Neueste Nachrichten
Weekly Trades: Is Ensysce Biosciences Inc a turnaround story2026 Snapshot & Fast Exit and Entry Trade Guides - baoquankhu1.vn
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Ensysce Biosciences Files Certificate of Correction for Series B Preferred Stock with Delaware Secretary of State - Minichart
Ensysce Biosciences files correction to Series B preferred stock designation By Investing.com - Investing.com South Africa
Ensysce Biosciences Corrects Series B Preferred Stock Designation - TipRanks
Ensysce Biosciences files correction to Series B preferred stock designation - Investing.com
Ensysce Biosciences (ENSC) files correction to Series B preferred stock - Stock Titan
If You Invested $1,000 in Ensysce Biosciences Inc (ENSC) - Stock Titan
ENSC Stock Price, Quote & Chart | ENSYSCE BIOSCIENCES INC (NASDAQ:ENSC) - ChartMill
Earnings Recap: Is Travere Therapeutics Inc stock heavily shorted2026 Technical Patterns & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Risk Analysis: Is Ensysce Biosciences Inc being accumulated by smart money2026 Setups & Daily Profit Focused Screening - baoquankhu1.vn
Ensysce Biosciences Inc expected to post a loss of $1.26 a shareEarnings Preview - TradingView
Market Fear: Will Ensysce Biosciences Inc benefit from geopolitical trendsJuly 2025 Setups & Smart Swing Trading Alerts - baoquankhu1.vn
Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future Pl - PharmiWeb.com
CEO takes live questions on Ensysce PF614 pain-drug plans - Stock Titan
Ensysce publishes phase 1 data on overdose-limiting opioid tech By Investing.com - Investing.com Australia
ENSC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
10 Health Care Stocks Moving In Monday's Pre-Market Session - Sahm
Ensysce publishes phase 1 data on overdose-limiting opioid tech - Investing.com India
New opioid design limits drug release when too many pills are swallowed - Stock Titan
Promising Penny Stocks To Add to Your Watchlist – March 1st - Defense World
Ensysce Biosciences, Inc. (NASDAQ:ENSC) Short Interest Down 15.8% in February - Defense World
Dow Dips Over 600 Points; US Producer Prices Increase In January - Sahm
Top Penny Stocks To Follow TodayFebruary 27th - MarketBeat
Ensysce Biosciences Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Nasdaq warns Ensysce Biosciences (ENSC) over sub-$1 minimum bid price - Stock Titan
Tiny Pain-Focused Biotech Ensysce Biosciences Surges Amid Strategic Review - Benzinga
Why Applied Optoelectronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Benzinga
Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value - Corsicana Daily Sun
Opioid safety drug developer Ensysce explores deals, possible asset sales - Stock Titan
Market Overview: Is Ensysce Biosciences Inc subject to activist investor interest2025 Market Outlook & Weekly Watchlist of Top Performers - baoquankhu1.vn
Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events - Corsicana Daily Sun
Drug developer Ensysce invited to 2026 pain and substance use research forums - Stock Titan
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Can Ensysce Biosciences Inc. continue delivering strong returnsJuly 2025 Momentum & Reliable Entry Point Alerts - mfd.ru
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Ensysce Biosciences files to sell 29.47M shares of common stock for holders - Intellectia AI
Why Ensysce Biosciences Inc. stock remains a top recommendationDip Buying & Free Community Consensus Stock Picks - mfd.ru
Why Ensysce Biosciences Inc. stock is a must watch in 2025Trade Entry Report & Daily Volume Surge Trade Alerts - mfd.ru
ENSC Should I Buy - Intellectia AI
Is Ensysce Biosciences Inc. subject to activist investor interestQuarterly Performance Summary & Verified Technical Signals - mfd.ru
RSI Check: Will Ensysce Biosciences Inc benefit from geopolitical trends2025 Trading Volume Trends & Weekly Sector Rotation Insights - baoquankhu1.vn
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Ensysce Biosciences Reaches 50% Enrollment Milestone In Pivotal Phase 3 Trial Of PF614 - Nasdaq
Ensysce Biosciences reaches 50% enrollment in Phase 3 pain drug trial - Investing.com Nigeria
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Does Ensysce Biosciences Inc. meet Warren Buffett’s criteriaEarnings Risk Summary & Capital Efficient Trade Techniques - mfd.ru
Ensysce Biosciences CEO says 'positioned for continued momentum' - MSN
Ensysce Biosciences reaches 50% enrollment in Phase 3 pain drug trial By Investing.com - Investing.com South Africa
New Highs: Does JPMPRM outperform in volatile marketsTrade Volume Report & Stock Timing and Entry Methods - baoquankhu1.vn
Chronic and Acute Pain Clinical Trial Pipeline Analysis: 150+ Key Companies Shaping the Future of Chronic and Acute Pain Therapeutics | DelveInsight - GlobeNewswire Inc.
Ensysce Flat on Review News - Baystreet.ca
Opioid designed to stay inactive until swallowed hits Phase 3 milestone - stocktitan.net
Rate Hike: Will The Western Union Company benefit from geopolitical trendsBond Market & Fast Gain Stock Tips - baoquankhu1.vn
Merger Talk: Is Ensysce Biosciences Inc stock showing strong momentumQuarterly Trade Summary & Low Risk Investment Opportunities - baoquankhu1.vn
Ensysce Biosciences receives patent allowance in Brazil for pain tech By Investing.com - Investing.com Canada
Ensysce Biosciences receives patent allowance in Brazil for pain tech - Investing.com
New Brazil patent backs Ensysce bid for safer opioid pain drugs - Stock Titan
Volume Recap: Is Ensysce Biosciences Inc stock dividend yield sustainableTrade Exit Report & Low Risk High Win Rate Picks - Bộ Nội Vụ
Panic Selling: Why Ensysce Biosciences Inc. stock is seen as undervaluedJuly 2025 Big Picture & Detailed Earnings Play Strategies - Bộ Nội Vụ
0.99%
3.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):